NASDAQ:ATRC AtriCure (ATRC) Stock Forecast, Price & News $43.80 -0.11 (-0.25%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$43.54▼$44.6450-Day Range$41.12▼$57.7352-Week Range$32.51▼$59.61Volume403,778 shsAverage Volume301,862 shsMarket Capitalization$2.08 billionP/E RatioN/ADividend YieldN/APrice Target$65.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media AtriCure MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside48.4% Upside$65.00 Price TargetShort InterestBearish2.83% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.89Based on 7 Articles This WeekInsider TradingSelling Shares$195,077 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.93) to ($0.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector391st out of 972 stocksSurgical & Medical Instruments Industry48th out of 96 stocks 3.5 Analyst's Opinion Consensus RatingAtriCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $65.00, AtriCure has a forecasted upside of 48.4% from its current price of $43.80.Amount of Analyst CoverageAtriCure has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.83% of the outstanding shares of AtriCure have been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in AtriCure has recently increased by 8.94%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATRC. Previous Next 3.8 News and Social Media Coverage News SentimentAtriCure has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for AtriCure this week, compared to 2 articles on an average week.Search Interest1 people have searched for ATRC on MarketBeat in the last 30 days. MarketBeat Follows3 people have added AtriCure to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $195,077.00 in company stock.Percentage Held by InsidersOnly 3.00% of the stock of AtriCure is held by insiders.Percentage Held by Institutions94.30% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AtriCure are expected to grow in the coming year, from ($0.93) to ($0.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is -71.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is -71.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 4.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AtriCure (NASDAQ:ATRC) StockAtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.Read More ATRC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATRC Stock News HeadlinesOctober 1, 2023 | americanbankingnews.comAtriCure (NASDAQ:ATRC) Coverage Initiated at UBS GroupSeptember 30, 2023 | msn.comUBS Initiates Coverage of Atricure (ATRC) with Buy RecommendationOctober 1, 2023 | Behind the Markets (Ad)U.S. Loses to China in Shocking WAR GAMES=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>September 25, 2023 | americanbankingnews.comAtriCure, Inc. (NASDAQ:ATRC) Receives $66.80 Consensus PT from AnalystsSeptember 9, 2023 | finance.yahoo.comUnveiling AtriCure (ATRC)'s Value: Is It Really Priced Right? A Comprehensive GuideAugust 29, 2023 | seekingalpha.comAtriCure: Core Growth Markets Expanding, But Could Be Well Priced InAugust 16, 2023 | finance.yahoo.comIs It Too Late To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?July 29, 2023 | gurufocus.comInsider Sell: AtriCure Inc's Chief Legal Officer Karl Dahlquist Sells 3,417 SharesOctober 1, 2023 | Behind the Markets (Ad)U.S. Loses to China in Shocking WAR GAMES=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>July 27, 2023 | finance.yahoo.comAtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 63% Above Its Share PriceJuly 27, 2023 | finance.yahoo.comAtriCure Reports Second Quarter 2023 Financial ResultsJuly 27, 2023 | washingtonpost.comAtriCure: Q2 Earnings SnapshotJuly 27, 2023 | msn.comNeedham Maintains Atricure (ATRC) Buy RecommendationJuly 27, 2023 | finance.yahoo.comAtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesJuly 27, 2023 | finance.yahoo.comQ2 2023 AtriCure Inc Earnings CallJuly 24, 2023 | markets.businessinsider.comWhat Wall Street expects from AtriCure's earningsJuly 3, 2023 | finance.yahoo.comAtriCure to Announce Second Quarter 2023 Financial ResultsJune 14, 2023 | seekingalpha.comAtriCure: Operating Leverage Is Required As A CureJune 6, 2023 | finance.yahoo.comATRC - AtriCure, Inc.June 2, 2023 | msn.comNeedham Reiterates Atricure (ATRC) Buy RecommendationJune 2, 2023 | markets.businessinsider.comNeedham Reaffirms Their Buy Rating on Atricure (ATRC)May 25, 2023 | finance.yahoo.comUPDATE 1-Abu Dhabi makes its Falcon 40B AI model open sourceMay 23, 2023 | uk.finance.yahoo.comAtriCure, Inc. (ATRC)May 4, 2023 | finance.yahoo.comAtriCure First Quarter 2023 Earnings: Beats ExpectationsMay 3, 2023 | finance.yahoo.comQ1 2023 AtriCure Inc Earnings CallMay 2, 2023 | finance.yahoo.comAtriCure Reports First Quarter 2023 Financial ResultsApril 19, 2023 | finance.yahoo.comAtriCure to Participate in the 2023 Bank of America Health Care Conference and Host a Cryo Nerve Block Therapy Investor Education WebcastSee More Headlines Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRC Company Calendar Last Earnings7/25/2023Today10/01/2023Next Earnings (Estimated)11/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:ATRC CUSIP04963C20 CIK1323885 Webwww.atricure.com Phone(513) 755-4100Fax513-755-4567Employees1,050Year Founded2000Price Target and Rating Average Stock Price Forecast$65.00 High Stock Price Forecast$74.00 Low Stock Price Forecast$56.00 Forecasted Upside/Downside+48.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,470,000.00 Net Margins-7.67% Pretax Margin-7.57% Return on Equity-7.11% Return on Assets-5.54% Debt Debt-to-Equity Ratio0.12 Current Ratio3.33 Quick Ratio2.56 Sales & Book Value Annual Sales$330.38 million Price / Sales6.28 Cash FlowN/A Price / Cash FlowN/A Book Value$9.82 per share Price / Book4.46Miscellaneous Outstanding Shares47,400,000Free Float45,978,000Market Cap$2.08 billion OptionableOptionable Beta1.37 Social Links The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Michael H. Carrel (Age 52)CEO, Pres & Director Comp: $1.62MMs. Angela L. Wirick CPA (Age 45)Chief Financial Officer Comp: $668.62kMr. Douglas J. Seith (Age 57)Chief Operating Officer Comp: $989.17kMr. Justin J. Noznesky (Age 45)Chief Marketing & Strategy Officer Comp: $644.73kMs. Deborah Yount (Age 57)Chief HR Officer Comp: $498.36kMr. Salvatore Privitera J.D. (Age 56)Chief Technical Officer Dr. Vinayak Doraiswamy Ph.D. (Age 51)Chief Scientific Officer Mr. Karl S. Dahlquist C.C.E.P. (Age 53)CCEP, J.D., Chief Legal Officer Valerie Storch-WillhausVP of Corp. Marketing & CommunicationsMore ExecutivesKey CompetitorsAlphatecNASDAQ:ATECIntegra LifeSciencesNASDAQ:IARTGlobus MedicalNYSE:GMEDNovoCureNASDAQ:NVCRPROCEPT BioRoboticsNASDAQ:PRCTView All CompetitorsInsiders & InstitutionsBarclays PLCSold 6,561 shares on 9/21/2023Ownership: 0.044%Portside Wealth Group LLCBought 83,181 shares on 9/1/2023Ownership: 0.175%Comerica BankBought 16,099 shares on 8/22/2023Ownership: 0.034%California State Teachers Retirement SystemBought 1,423 shares on 8/21/2023Ownership: 0.121%Legato Capital Management LLCBought 7,144 shares on 8/18/2023Ownership: 0.053%View All Insider TransactionsView All Institutional Transactions ATRC Stock - Frequently Asked Questions Should I buy or sell AtriCure stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATRC shares. View ATRC analyst ratings or view top-rated stocks. What is AtriCure's stock price forecast for 2023? 5 Wall Street research analysts have issued twelve-month target prices for AtriCure's stock. Their ATRC share price forecasts range from $56.00 to $74.00. On average, they predict the company's stock price to reach $65.00 in the next year. This suggests a possible upside of 48.4% from the stock's current price. View analysts price targets for ATRC or view top-rated stocks among Wall Street analysts. How have ATRC shares performed in 2023? AtriCure's stock was trading at $44.38 on January 1st, 2023. Since then, ATRC stock has decreased by 1.3% and is now trading at $43.80. View the best growth stocks for 2023 here. When is AtriCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023. View our ATRC earnings forecast. How were AtriCure's earnings last quarter? AtriCure, Inc. (NASDAQ:ATRC) released its earnings results on Tuesday, July, 25th. The medical device company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.15. The medical device company had revenue of $100.92 million for the quarter, compared to analyst estimates of $97.55 million. AtriCure had a negative trailing twelve-month return on equity of 7.11% and a negative net margin of 7.67%. The company's revenue for the quarter was up 19.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.32) EPS. What ETFs hold AtriCure's stock? ETFs with the largest weight of AtriCure (NASDAQ:ATRC) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Nuveen Small Cap Select ETF (NSCS), Simplify Health Care ETF (PINK), Harbor Corporate Culture Small Cap ETF (HAPS), Principal Healthcare Innovators ETF (BTEC) and Invesco Nasdaq Future Gen 200 ETF (QQQS).iShares U.S. Medical Devices ETF (IHI). What guidance has AtriCure issued on next quarter's earnings? AtriCure issued an update on its FY 2023 earnings guidance on Tuesday, July, 25th. The company provided EPS guidance of -$0.94--$0.92 for the period, compared to the consensus EPS estimate of -$1.02. The company issued revenue guidance of $392.00 million-$395.00 million, compared to the consensus revenue estimate of $388.31 million. What is Michael Carrel's approval rating as AtriCure's CEO? 38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Pfizer (PFE) and Sarepta Therapeutics (SRPT). What is AtriCure's stock symbol? AtriCure trades on the NASDAQ under the ticker symbol "ATRC." How do I buy shares of AtriCure? Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AtriCure's stock price today? One share of ATRC stock can currently be purchased for approximately $43.80. How much money does AtriCure make? AtriCure (NASDAQ:ATRC) has a market capitalization of $2.08 billion and generates $330.38 million in revenue each year. The medical device company earns $-46,470,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. How many employees does AtriCure have? The company employs 1,050 workers across the globe. Does AtriCure have any subsidiaries? The following companies are subsidiares of AtriCure: SentreHEART.Read More How can I contact AtriCure? AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The official website for the company is www.atricure.com. The medical device company can be reached via phone at (513) 755-4100, via email at lynn@gilmartinir.com, or via fax at 513-755-4567. This page (NASDAQ:ATRC) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.